Ridaforolimus
File:Deforolimus.svg | |
Systematic (IUPAC) name | |
---|---|
(1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate | |
Identifiers | |
CAS Number | 572924-54-0 |
ATC code | none |
PubChem | CID 11520894 |
Chemical data | |
Formula | C53H84NO14P |
Molar mass | Script error: No such module "math". g·mol−1 |
Ridaforolimus (also known as AP23573 and MK-8669; formerly known as Deforolimus[1]) is an immunosuppressant currently undergoing research for the treatment of certain cancers. It is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis.
Ridaforolimus is being co-developed by Merck and ARIAD Pharmaceuticals. As of 2008[update], a phase III clinical trial of ridaforolimus in metastatic soft-tissue and bone sarcomas responsive to chemotherapy, SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus), is recruiting patients.[2][3]
On May 5, 2010, Ariad Pharmaceuticals and Merck & Company announced a clinical development and marketing agreement. With this agreement, Ariad will receive an upfront payment of $50 million with an additional $19 million reimbursement for R&D expenses incurred to date in the program. Future payments are triggered upon acceptance of the NDA by the FDA with another payment when the drug receives marketing approval. There are similar milestones for acceptance and approval in both Europe and Japan. Other milestone payments are tied to revenue goals for the drug.[4]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ "ARIAD Reports First Quarter 2009 Development Progress and Financial Results- Ridaforolimus New USAN Name to Replace Deforolimus". ARIAD Pharmaceuticals. 2009. Retrieved 2009-05-07.
- ↑ "SUCCEED: Landmark Global Phase 3 Trial Now Enrolling!". ARIAD Pharmaceuticals. 2008. Retrieved 2008-04-18.
- ↑ Deforolimus (AP23573) in Treatment of Sarcoma - SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Deforolimus) Study. ClinicalTrials.gov (2008-03-07). Retrieved on 2008-04-18.
- ↑ http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1422441&highlight=
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Articles containing potentially dated statements from 2008
- Articles with invalid date parameter in template
- All articles containing potentially dated statements
- 2Fix
- Immunosuppressants
- Macrolides
- Antineoplastic and immunomodulating drug stubs